The FDA has given its nod to Edwards Lifesciences' second generation heart valve replacement system for aortic stenosis patients who are too weak to undergo open heart surgery. The device is set to compete with Medtronic's CoreValve.
The FDA has given its nod to Edwards Lifesciences' second generation heart valve replacement system for aortic stenosis patients who are too weak to undergo open heart surgery. The device is set to compete with Medtronic's CoreValve.